NEW YORK (GenomeWeb News) – UK-based Asterand today said that it will acquire BioSeek, a developer of cell-based assay systems, in a deal worth up to $14 million.
Asterand, which provides tissue-based services for drug discovery, said that the acquisition will provide it with highly complementary technologies, specifically BioSeek's BioMap platform and human cell-based assays.